Valaciclovir showed no clear difference in CMV disease compared with ganciclovir or valganciclovir (low certainty).
Valaciclovir showed no clear difference in all‐cause death compared with ganciclovir or valganciclovir (low certainty).
Valaciclovir showed no clear difference in CMV infection compared with ganciclovir or valganciclovir (low certainty).
It is very uncertain whether valaciclovir changes acute rejection compared with ganciclovir or valganciclovir (very low certainty).
Valaciclovir showed no clear difference in graft loss compared with ganciclovir or valganciclovir (low certainty).
Valaciclovir showed no clear difference in leucopenia compared with ganciclovir or valganciclovir (moderate certainty).
Extended probably leads to lower CMV disease compared with short‐duration valganciclovir (moderate certainty).
Extended showed no clear difference in all‐cause death compared with short‐duration valganciclovir (low certainty).
Extended probably leads to lower CMV syndrome compared with short‐duration valganciclovir (moderate certainty).
Extended may leads to lower CMV infection compared with short‐duration valganciclovir (low certainty).
Extended probably leads to lower acute rejection compared with short‐duration valganciclovir (moderate certainty).
Extended showed no clear difference in opportunistic infections compared with short‐duration valganciclovir (low certainty).
Extended showed no clear difference in total treatment‐related adverse effects compared with short‐duration valganciclovir (moderate certainty).
Low showed no clear difference in all‐cause death compared with standard dose valganciclovir (low certainty).
Low showed no clear difference in CMV infection compared with standard dose valganciclovir (low certainty).
Low showed no clear difference in acute rejection compared with standard dose valganciclovir (low certainty).
Low showed no clear difference in graft loss compared with standard dose valganciclovir (low certainty).
The review found no eligible studies for this question.